Sugi Predict

Sugi Predict / Compounds / SCHEMBL3703474

SCHEMBL3703474

SCHEMBL3703474

CC1(C)C(=O)Nc2cc(Nc3nc(NC4CC4)c4occc4n3)ccc21

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 15/20 0.76
▸ LCK P06239 3/20 0.58
▸ KDR P35968 3/20 0.58
▸ JAK2 O60674 2/20 0.58
▸ STK16 O75716 2/20 0.58
▸ ABL1 P00519 2/20 0.58
▸ FYN P06241 2/20 0.58
▸ RET P07949 2/20 0.58
▸ LTK P29376 2/20 0.58
▸ MAPK8 P45983 2/20 0.58
▸ PTK2 Q05397 2/20 0.58
▸ TNK2 Q07912 2/20 0.58
▸ MAP4K2 Q12851 2/20 0.58
▸ DAPK3 O43293 1/20 0.58
▸ MAP4K4 O95819 1/20 0.58
▸ PAK4 O96013 1/20 0.58
▸ TTK P33981 1/20 0.58
▸ GRK5 P34947 1/20 0.58
▸ CSNK1A1 P48729 1/20 0.58
▸ TYRO3 Q06418 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3697246 0.96 SYK (0.71) SYKLCKKDRJAK2STK16
SCHEMBL3716960 0.89 SYK (0.61) SYKLCKKDRJAK2STK16
SCHEMBL1709850 0.87 SYK (0.71) SYKLCKKDRJAK2STK16
SCHEMBL1709929 0.85 SYK (0.70) SYKLCKKDRJAK2STK16
SCHEMBL3714523 0.85 SYK (0.66) SYKLCKKDRJAK2STK16
SCHEMBL7622611 0.85 SYK (0.55) SYKLCKKDRJAK2STK16
SCHEMBL3704657 0.84 SYK (0.66) SYKLCKKDRJAK2STK16
SCHEMBL3705241 0.83 SYK (0.73) SYKLCKKDRJAK2STK16
SCHEMBL3713456 0.83 SYK (0.73) SYKLCKKDRJAK2STK16
SCHEMBL3709370 0.82 SYK (0.74) SYKLCKKDRJAK2STK16

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US claimed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US claimed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-8551981-B2 Furo[3,2-d]pyrimidine compounds ABBVIE INC. (US) 2013-10-08 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-05-17 — — US disclosed
WO-2012048222-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122846-A1 FURO[3,2-d]PYRIMIDINE COMPOUNDS CDK2, DPYD, CDK3 SYK 1176/4885LCK 154/4885KDR 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.